OPKO Health to Present at Upcoming September Conferences
MIAMI, Aug. 31, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (“OPKO” or “the Company”), announces that management will present a corporate update, which will include an update on its hGH development program, at the following upcoming September 2017 investor conferences:
2017 Wells Fargo Healthcare Conference
Date and Time: Thursday, September 7, 2017 at 11:10 a.m. Eastern time
Venue: Westin Boston Waterfront Hotel, Boston, MA
Format: Company presentation
Cantor Fitzgerald Global Healthcare Conference
Date and Time: Monday, September 25, 2017 at 3:35 p.m. Eastern time
Venue: InterContinental New York Barclay Hotel, New York, NY
Format: Company presentation
Ladenburg Thalmann 2017 Healthcare Conference
Date and Time: Tuesday, September 26, 2017 at 11:30 a.m. Eastern time
Venue: Sofitel New York Hotel, New York, NY
Format: Company presentation
10th Annual Barrington Fall Investment Conference
Date and Time: Wednesday, September 27
Venue: The Palmer House Hilton, Chicago, IL
Format: One-on-One Investor Meetings
The presentations will be webcast live and can be accessed on the Investor Relations section of the Company’s website at www.opko.com where they will be archived for a period of time.
About OPKO Health, Inc.
OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI® for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and OPK88004, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia in phase 2a. We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com.
Contacts: Company OPKO Health, Inc. David Malina, 305-575-4100 Investor Relations dmalina@opko.com LHA Investor Relations Anne Marie Fields, 212-838-3777 afields@lhai.com or Bruce Voss, 310-691-7100 bvoss@lhai.com
Released August 31, 2017